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Summary Response to chemotherapy and survival was retrospectively analyzed in 28 patients with bulky
retroperitoneal and disseminated seminoma treated between 1977 and 1983. The median age was 41 years
(range: 23-52). All patients had histological evidence of pure testicular seminoma, however, 14 patients
revealed moderate increases of human fi-chorionic gonadotropin levels. Prior radiotherapy had been given to
9/28 (32%) patients. Treatment consisted of at least four courses of simultaneous or sequentially alternating
therapy with cisplatin, vinblastine, bleomycin plus/minus adriamycin (PVB ±A), administration of ifosfamide
or combination therapy with ifosfamide/cisplatin (IFS/DDP) or ifosfamide/etoposide (IFS/ETP). Twenty-five
of 28 patients (89%) achieved a complete (CR), and 3/28 patients a partial remission. Relapse occurred in 1/8
CR patients after adjuvant postchemotherapeutic irradiation, and in 1/11 patients without any further
radiotherapy. So far, 23/28 patients (82%) are free of disease after a median follow-up of 28 + (14+ --82+)
months. Marked myelosuppression was observed in previously irradiated patients, mainly after PVB+A
therapy. In two patients, transient nephrotoxicity developed after PVB and IFS/DDP, respectively. After
PVB+A chemotherapy, three patients revealed polyneuropathy, paralytic subileus and bleomycin-induced
pneumonitis, respectively. In conclusion, the present series suggests a high probability of continuous CR in
even bulky retroperitoneal and widespread metastatic seminoma. So far, no definite conclusions can be made
on the therapeutic superiority of one of the different chemotherapeutic regimens used. However, this
preliminary experience suggests that the combination of ifosfamide and etoposide or cisplatin may prove less
toxic than sequentially alternating or simultaneous PVB+A chemotherapy.
Seminomas, which account for -40% (27-71%) of
testicular cancers, generally tend to present as local
(Stage I) or locoregional (Stage II) disease in 70-
90% of the patients (Calman et al., 1979; Dixon &
Moore, 1952; Maier et al., 1968; Mostofi, 1973;
Thomas et al., 1982). Orchiectomy and retro-
peritoneal radiotherapy in Stage I and minimal
Stage II disease usually result in an excellent overall
prognosis, with 5-year survival rates approaching
90%. However, long-term results have remained
rather poor with up to 40-50% relapses when
radiotherapy served as the sole treatment of bulky
Stage II disease (Ball et al., 1982; Smith et al.,
1979; Thomas et al., 1982).
Besides some early trials reporting on the
sensitivity of metastatic seminomas to single agent
chemotherapy, recent studies, mostly utilizing
cisplatin containing regimens originally employed
for the treatment of nonseminomatous testicular
cancer have described a 50-70% or even higher
complete remission rate (Ball et al., 1982;
Mendenhall et al., 1981; Vugrin & Whitmore,
1984). However, most series contained only a small
number of patients, thereby precluding any
definitive conclusion on the value of the regimens
used. In addition, significant toxicity, pre-
dominantly occurring in previously irradiated
patients, has been observed with most of these
regimens.
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Nevertheless, cytostatic chemotherapy appears to
be the treatment of choice not only for widespread
metastatic, but also for bulky retroperitoneal
disease. In the present retrospective analysis, the
efficacy and toxicity ofdifferent combination chemo-
therapies in the treatment of advanced disseminated
seminomas has been studied.
Materials and methods
Patients
This report includes 28 patients with histologically
confirmed pure seminoma of the testis who
presented at our institution between 1977 and 1983.
None of these patients had received prior
chemotherapy. Patient characteristics are shown in
Table I. The median age was 41 years (range: 23-52
years). Histological examination revealed a poorly
differentiated (anaplastic) seminoma in 6 patients
(21%) and a well differentiated (classical or typical)
seminoma in 22 patients (79%). Fourteen patients
(50%) showed a moderate elevation of human
chorionic gonadotropin (f-hCG) serum levels prior
to chemotherapy, which did not exceed
70mIUmlP- (normal: <5mIUml-1) in 12/14
patients. Two patients demonstrated f-hCG levels
of 150 and 210mIUml- without any histological
evidence of nonseminomatous tumour elements.
Pretreatment
Patients were usually referred to our institution
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Table I Patient characteristics
No. of evaluable pts : 28
Median age : 41 y (range: 23-52)
Histology
poorly differentiated : 6/28 (21%)
well differentiated : 22/28 (79%)
Tumour marker
AFP elevation : 0/28
fl-HCG elevation : 14/28 (50%)
Pretreatment
Irradiation : 9/28 (32%)
retroperitoneal : 5
retroperitoneal, mediastinal+
supraclavicular 4
Laparotomy 7/28 (25%)
following the initial orchiectomy performed at other
hospitals. Nine of the 28 patients (32%) had been
previously treated with retroperitoneal (n=5), or
retroperitoneal, mediastinal and supraclavicular
(n=4) irradiation. Another 7 patients with Stage II
C disease had undergone a prior laparotomy for
diagnostic and staging purposes.
Staging procedures
Clinical staging generally included physical
examination, chest X-rays, routine blood chemistry
monitoring, abdominal sonograms, intravenous
urography, liver and bone scans and lymphography
when indicated, and, since 1979, computerized
tomograms. In addition, serum was routinely
collected for alpha-fetoprotein (AFP) and #-hCG
determinations.
The Staging classification used has been
originally developed for nonseminomatous testi-
cular cancer (Seeber et al., 1980; Schuette et al.,
1983):
-Stage II B: Retroperitoneal lymph node
metastases, >2 and <5cm in diameter.
Stage II C: Bulky retroperitoneal disease,
metastases >5cm in maximum diameter, in most
cases palpable, often with ureteral displacement.
-Stage III: Infra- and supradiaphragmatic lymph
node metastases.
-Stage IV A: Minimal pulmonary with no
measurable abdominal disease.
Stage IV B: Advanced pulmonary (>10cm3)
with no measurable abdominal disease.
Stage IV C: Minimal pulmonary and abdominal
(>2, <5cm) disease.
Stage IV D: Advanced pulmonary and
abdominal disease (>5cm) plus/minus
extralymphatic metastases (liver, bone, brain,
etc.).
One patient was classified as having Stage II B
disease after previous laparotomy and an
untraoperative macroscopic dissemination of viable
tumour material; in addition, the fl-hCG level was
slightly elevated prior to chemotherapy. Fourteen
patients presented with Stage II C, including 11/14
patients with maximum tumour diameters >1Ocm.
One patient had Stage III, and 4 patients Stage IV
C disease. Stage IV D disease was recorded in 8
patients.
Treatment schedules
During the past 7 years different chemotherapeutic
regimens have been used at our institution. From
1977-1980, chemotherapy of advanced metastatic
seminomas closely resembled our treatment policy
for nonseminomatous testicular tumours, consisting
of the sequentially alternating administration of
vinblastine/bleomycin and cisplatin/adriamycin in
9/28 patients (Niederle et al., 1983; Scheulen et al.,
1980; Schuette et al., 1983). Treatment schedules
and doses are shown in Table II. Two patients
received the 3-drug combination of cisplatin,
vinblastine and bleomycin (Einhorn & Donohue,
1979). Since 1980/81, mainly in the lights of some
favourable results of early Phase II trials,
chemotherapy of seminomas primarily consisted of
ifosfamide, either alone or in combination with
etoposide or cisplatin. Most patients received at
least 4 courses (range: 4-9) of the fractionated
chemotherapy with either regimen. Generally,
treatment was repeated for at least 2 courses after
the induction of complete remission.
Table II Treatment schedules (repeated every 3-4 weeks)
I Sequentially alternating chemotherapy, starting with
either 2 courses ofadriamycin/cisplatin or
vinblastine/bleomycin. After 4 courses of
chemotherapy, treatment was adapted to the
individual needs.
Adriamycin 60mgm-2 i.v., Day 1
Cisplatin 20mgm-2 i.v., Days 1-5
Vinblastine 0.15-0.2mgkg-1 i.v., Days 1+2
Bleomycin 30mg i.v., Days 1-5
(continuous infusion)
II Simultaneous 3-drug regimen:
Cisplatin 20mgm-2 i.v., Days 1-5
Vinblastine 0.15mgkg-1 i.v., Days 1+2
Bleomycin 30mg i.v., Days 1, 8+ 15
III Ifosfamide 60-80mgkg 1 i.v., Days 1-5
IV Ifosfamide 40-50mgkg-1 i.v., Days 1-5
Etoposide 100-120mg-2 i.v., Days 1, 3+5
V Ifosfamide 40-50mg 1 i.v., Days 1-5
Cisplatin 20mgm 2 i.v., Days 1-5
Response criteria
Tumour response was assessed before each
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treatment course. Objective response was classified
according to standard criteria (Miller et al., 1981):
Complete remission (CR) was defined as the
disappearance of all evaluable tumour parameters
for at least one month. Partial remission (PR) was
a more than 50% reduction of tumour volume.
Results
Response
All patients considered in this review were
evaluable for response. Treatment results in relation
to tumour stage are shown in Table III. The
response rate was 100% with 25/28 patients (89%)
achieving a complete, and 3/28 patients (11%) a
partial remission.
Treatment results with regard to the different
chemotherapeutic regimens used are given in Table
IV. Complete remission was achieved in 7/7,
patients treated with ifosfamide/cisplatin, and in 6/7
patients following ifosfamide/etoposide combination
therapy. With the latter regimen one PR was attained
in a patient after extensive prior irradiation.
Ifosfamide alone resulted in 3/3 CR with one
patient relapsing after 11 months. This patient was
further salvaged by retroperitoneal irradiation.
Sequentially alternating chemotherapy with cisplatin/
adriamycin and vinblastine/bleomycin resulted in 8/9
CR. The simultaneous combination of cisplating,
vinblastine and bleomycin (PVB) produced one
complete and one partial remission.
Comparing the number of treatment cycles
necessary for CR induction, sequentially alternating
and PVB chemotherapy resulted in a median of 3,
treatment with ifosfamide combination therapy in a
median of 2 treatment courses.
Since experience with nonseminomatous testicular
cancer suggested a useful role of adjuvant surgery
for bulky retroperitoneal disease in increasing long-
term survival, and 3-hCG elevations might
represent some nonseminomatous tumour elements
in even "pure" seminomas, retroperitoneal lymph
node dissection following the chemotherapeutic CR
induction was performed in 6/14 ,B-hCG positive
patients who initially presented with Stage II C
disease. In each of these patients necrosis and dense
fibrosis but no viable tumour residues were
discovered by histological examination.
Overall, the outcome of treatment with regard to
the presence of,-hCG increases is shown in Table
V. Twelve of 14 fl-hCG positive patients (86%)
achieved CR with 10/14 patients still being alive
and currently free of disease. One of the group of 4
treatment failures had Stage III, and 3/4 patients
stage IV disease. On the other hand, 13/14 tumour
marker negative patients (93%) attained CR. So
far, all 14 patients are alive and free of disease,
Table III Response to chemotherapy by stage of seminoma
II B IIC III IVC IV D Total
Stage (n=J) (n=14) (n=1) (n=4) (n=8) (n=28)
CR 1 14 1 3 6 25
Relapse 1 1 1 3
presently NED' 1 14b 2 6 23b
NED: no evidence ofdisease.
amedian follow-up: 28+ months.
bincluding one patient who attained a second CR following radiotherapy.
Table IV: Outcome of treatment by chemotherapy
DDP/ADM
+
VLB/BIM DDP, VLB, BLM IFS IFS/DDP IFS/ETP
(n =9) (n=2) (n=3) (n=7) (n=7)
CR 8 1 3 7 6
PR 1 1 1
Relapse 2 - 1
presently NED 6 1 3 7 6
NED: no evidence ofdisease (median follow-up 28+ months).
DDP: cisplatin, ADM: adriamycin, VLB: vinblastine.
BLM: bleomycin, IFS: ifosfamide, ETP: etoposide.470 J. SCHUETTE et al.
Table V Results of chemotherapy in relation
to serum P-HCG levels (n=28)
P-HCG P-HCG not
elevated elevated
(n=14) (n=14)
CR 12 13
presently NED 10 13
including on PR patient who was salvaged with
additional radiotherapy for residual retroperitoneal
disease.
Influence ofradiotherapy on treatment results
Complete remission was achieved in 7/9 previously
irradiated patients (78%) and in 18/19 patients
(95%) who had not received prior radiotherapy.
Partial remission in both groups was observed only
in Stage IV disease. Both previously irradiated PR
patients had developed significant myelosuppression
during chemotherapy requiring intensive supportive
care, prolongation of treatment intervals and
cytostatic dose reductions which might account for
the treatment failure.
Eight patients with chemotherapy-induced CR
were further allocated for an adjuvant irradiation
of the primary advanced retroperitoneal (n=7)
and/or mediastinal disease(n =3). One of these
patients relapsed after 14 months and could not be
salvaged by subsequent chemotherapy due to severe
myelosuppression. In contrast, only one of 11 CR
patients who did not receive prior radiotherapy or
adjuvant irradiation after previous chemotherapy
relapsed 11 months after ifosfamide and achieved a
second CR following irradiation of recurrent
retroperitoneal disease.
Survival
All patients are evaluable for a minimum follow-up
of one year. Remission duration of CR patients
ranges between 14+ and 82 + months (median:
28+), compared to 3, 10 and 15+ months in
partial responders. Overall median survival is 28+
months with a median of 31 + months for complete
responders (range: 15+-+86+). So far, two PR
and one CR patient died 12, 13 and 25 months
after start of chemotherapy, respectively (Table IV).
Toxicity
Side effects usually included alopecia and myelo-
suppression (Table VI). Significant reductions of
the standard cytostatic dosages were necessary in
almost all patients after prior irradiation. Platelet
transfusions and antibiotic treatment for severe
thrombo- and leukocytopenia were required in one
patient after PVB chemotherapy. Temporary
increases of serum creatinine concentrations were
observed in two patients after PVB and ifos-
famide/cisplatin, respectively. Long-lasting neuro-
toxic side effects due to vinblastine (and cisplatin)
became apparent in one patient after sequentially
alternating chemotherapy withvinblastine/bleomycin
and cisplatin/adriamycin. Interstitial lung fibrosis
after a total dose of 300mg of bleomycin occurred
in a 43-year old patient who had previously
received mediastinal irradiation. One patient
developed a paralytic subileus after PVB. Nausea
and vomiting usually occurred during cisplatin
therapy but were significantly less intense and only
Table VI Toxicity ofchemotherapy in metastatic seminoma
DDP/ADM
Type of +
side effect VBL/BLM DDP, VLB,BLM IFS IFS/DDP IFS/ETP
Leukocytopenia
<2000j1- 2/6 2/2 3/6 1/5
<1000/ 1- 1/6 1/2 -
Thrombocytopenia
<lO0,OOOpu-1 1/6 2/2 1/6
<50,000MI- 1/6 1/2
Alopecia 9/9 2/2 3/3 7/7 7/7
Nephrotoxicity
(creatinine> 1.2mg%) 1/2 - 1/7
Polyneuropathy 1/2
Pneumonitis/Lung fibrosis 1/9
Paralytic subileus 1/2
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infrequently recorded with ifosfamide and
ifosfamide/etoposide therapy.
Discussion
Since the original report by Blokhin et al. (1958)
demonstrating activity of cytostatic chemotherapy
in disseminated testicular seminoma, recent reports
of the use of single agent and combination chemo-
therapy have shown encouraging results suggesting
an at least similar chemosensitivity of disseminated
seminoma as compared to nonseminomatous
testicular cancer (Blokhin et al., 1958; Chebotareva,
1964; Golbey, 1970; Mackenzie, 1966; Monfardini
et al., 1972; Vugrin et al., 1981; Whitmore et al.,
1977). However, since only 5-15% of patients
initially present with advanced locoregional or
disseminated disease and only few patients relapse
after prior radiotherapy of minimal retroperitoneal
disease, most trials include only small numbers of
patients (Table VII). So far, chemotherapy with
cisplatin, vinblastine and bleomycin (PVB) has been
the most widely used combination resulting in a 50-
70% CR rate with most CR patients remaining free
of disease (Einhorn & Williams, 1980).
Nevertheless, significant morbidity preferably
occurring after prior radiotherapy has been
observed by several authors (Ball et al., 1982;
Mendenhall et al., 1981; Wajsman et al., 1983).
The present series including 28 patients with
widespread metastatic and/or advanced retro-
peritoneal seminoma has demonstrated an excellent
chemosensitivity with 23/28 (82%) patients being
currently free of disease after a median follow-up of
28 + months. Thus, in comparison to the 30-50%
actual long-term survival rates (median follow-
up .2 years) described for patients with similar
stages of advanced and bulky nonseminomatous
testicular cancer, disseminated seminoma in our
experience appears to be the germ cell cancer most
responsive to cytostatic chemotherapy (Einhorn &
Donohue, 1979; Niederle et al., 1983; Vugrin et al.,
1982). At present, no substantial data are available
to suggest therapeutic benefit from consolidating
radiotherapy in complete responders. In this series,
relapse occurred in one of 8 patients with and in
one of 11 patients without additional irradiation.
Similar to other reports, adjuvant retroperitoneal
lymph node dissection after chemotherapy as
carried out in 6/14 of the initially ,B-hCG positive,
bulky disease patients might be of only limited
value since microscopic tumour residues were
discovered in none of these patients (Vugrin &
Whitmore, 1984; Samuels et al., 1980). In addition,
complete lymphadenectomy was difficult to perform
because of the apparently dense fibrous tissue
found in the retroperitoneal area. Surgical
complications, however, did not occur.
In accordance with the results of several radio-
therapeutic trials, moderate elevation of P-hCG
levels, although suggesting the presence of non-
seminomatous, chorionic tumour elements, did not
seem, in our patients to adversely influence the
response and survival rates as compared to
serologically negative patients (Ball et al., 1982;
Javadpour et al., 1978; Mauch et al., 1979). The
treatment failures observed in ,B-hCG positive
patients might be due to the more advanced stage
of disease and/or prior irradiation.
In conclusion, the present series substantiates the
role of combination chemotherapy in advanced
Table VII Treatment results with chemotherapy in metastatic seminoma (selected literature)
Long-term Author
Treatment schedule No. pts CR (%) survival (%) (see under References)
VLB, BLM 11 4 (36) 2 (18) Samuels et al. (1980)
DDP, VCR, BLM, PRED
or 12 12 (100) 12 (100) Wajsman et al. (1983)
DDP, ETP
BLM, CTX, VCR, MTX, 5-FU 18 10 (55) 6 (33) Samuels et al. (1980)
DDP, VLB, BLM 8 4 (50) 8 (100)' Ball et al. (1982)
CTX, DDP 9 5 (55) 2 (22) Vugrin & Whitmore (1984)
CTX, DDP, BLM, VLB, Act D 7 7 (100) 5 (71) Vugrin & Whitemore (1984)
(VAB-6)
DDP, VLB, BLM+ADM 19 12 (63) 11 (58) Einhorn & Williams (1980)
Present series 28 25 (89) 23 (82)
aResults obtained following radiotherapy in partial responders.
DDP: cisplatin, BLM: bleomycin, VLB: vinblastine, ADM: adriamycin, CTX: cyclophosphamide, ETP:
etoposide, MTX: methotrexate, 5-FU: 5-fluorouracil, ActD: actinomycin D, PRED: prednisone, VCR:
vincristine.472 J. SCHUETTE et al.
seminoma. Since 80-90% of all relapses have been
shown to occur within 2-3 years after remission
induction, most of our complete responders
probably might attain continuous CR (Calman et
al., 1979; Thomas et al., 1982). However, with
respect to the limited number of patients and the
retrospective design of this analysis, no definite
conclusions can yet be made on the therapeutic
superiority of any one of the different chemo-
therapeutic regimens used. Nevertheless, this
preliminary experience suggests that the
combination of ifosfamide and etoposide or
cisplatin may prove equally effective and, most
importantly, less toxic as compared to the conven-
tional simultaneous or sequentially alternating
PVB+A chemotherapy.
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